Thrivent Financial for Lutherans Has $5.32 Million Stake in ANI Pharmaceuticals, Inc. $ANIP

Thrivent Financial for Lutherans boosted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 363.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,027 shares of the specialty pharmaceutical company’s stock after acquiring an additional 45,516 shares during the quarter. Thrivent Financial for Lutherans owned 0.27% of ANI Pharmaceuticals worth $5,315,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of ANIP. Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at about $28,000. Caitong International Asset Management Co. Ltd increased its position in ANI Pharmaceuticals by 4,636.4% during the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after buying an additional 510 shares during the last quarter. Newbridge Financial Services Group Inc. raised its stake in ANI Pharmaceuticals by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after buying an additional 400 shares during the period. State of Wyoming acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at approximately $50,000. Finally, CWM LLC boosted its stake in shares of ANI Pharmaceuticals by 159.1% during the 3rd quarter. CWM LLC now owns 798 shares of the specialty pharmaceutical company’s stock worth $73,000 after acquiring an additional 490 shares during the period. Institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ANIP shares. Guggenheim increased their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Barclays started coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target on the stock. Six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $103.43.

ANI Pharmaceuticals Trading Up 0.4%

Shares of ANI Pharmaceuticals stock opened at $81.84 on Friday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. The firm has a 50-day moving average of $81.64 and a 200-day moving average of $85.46. ANI Pharmaceuticals, Inc. has a 52-week low of $54.10 and a 52-week high of $99.50. The stock has a market cap of $1.84 billion, a PE ratio of 50.21 and a beta of 0.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business had revenue of $227.81 million during the quarter, compared to analysts’ expectations of $211.92 million. During the same quarter in the previous year, the company earned $1.34 EPS. The business’s revenue was up 53.6% on a year-over-year basis. As a group, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,622 shares of ANI Pharmaceuticals stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $82.40, for a total value of $133,652.80. Following the completion of the transaction, the senior vice president directly owned 58,564 shares of the company’s stock, valued at $4,825,673.60. The trade was a 2.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Chad Gassert sold 14,642 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $89.07, for a total value of $1,304,162.94. Following the sale, the senior vice president directly owned 158,584 shares in the company, valued at approximately $14,125,076.88. This trade represents a 8.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 28,101 shares of company stock valued at $2,453,063 in the last quarter. Corporate insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.